Dr Mercola interviews Dr Walsh; Role of nutrients for treating autism, anxiety, depression and dementia.

 

It only a matter of time before Dr Walsh and his nutritional protocol for treating mental disorders becomes mainstream. Thanks to popular health advocates such as Dr Mercola, Dr Walsh will get the exposure that is needed to wake up the medical community.

With the ever increasing ill effects on our epigenetics from the environment and the blind mis-use of medications to treat mental disorders, there is no better time than now to pay close attention to the research and perspective of Dr William Walsh in the treatment of autism, depression and all other mood and behavioral disorders.

Dr Mercola interviews Dr Walsh at a glance:

By Dr. Mercola

  • There are four biochemical types of violent people. Many have severe zinc deficiency, pyrrole disorder, low blood spermine and methylation defects — an unusual combination of bad biochemistry
  • While there are hundreds of nutrients that are important for health, in the brain, six or seven dominate. These are nutrients that are either involved in synthesis or functioning of neurotransmitters
  • Nutrients that have a powerful influence on mental health include zinc, copper, B-6, selenium, folates and S-adenosylmethionine (SAMe)

Can you use specific nutrients to improve your mental health? Yes, you can. William Walsh, Ph.D., president of the nonprofit Walsh Research Institute in Naperville, Illinois, and author of “Nutrient Power: Heal Your Biochemistry and Heal Your Brain,” specializes in nutrient-based psychiatry and nutritional medicine.

He and I are both  fellows of the American College of Nutrition. He’s designed nutritional programs for Olympic athletes, NBA players and major league baseball players. More importantly, he’s spent a great deal of his career seeking to improve mental health through nutrition.

“I started off in the hard science. I was an experimentalist,” Walsh says. “I worked, in the beginning, in the nuclear field … with places like Los Alamos, the Institute for Atomic Research and University of Michigan Research Institute. I wound up at Argonne National Laboratory. While working as a scientist there, I started a volunteer project at the local prison, Stateville Penitentiary.

I eventually got really interested in why people were violent …  [W]hen we started the ex-offender program, I got to meet the families that had produced a criminal. I found some wonderful families, caring and capable families, that have other children who turned out just fine …

I began to realize we didn’t understand why people had bad behavior. We then asked the question, ‘Could it be something related to their brain chemistry or the body chemistry?’… I started doing lab studies of their blood, their urine and hair. I found out that they were very, very different from the rest of the population. That’s how I got started.”

Biochemistry and the Criminal Brain

Walsh received valuable direction after meeting Dr. Carl Pfeiffer, who was doing work on heavy metals and schizophrenia. As it turns out, levels of metals, including copper, zinc and manganese, were all abnormal in criminals compared to the general population.

Walsh discovered four biochemical types of violent people. One of these was the sociopaths, all of whom had severe zinc deficiency, pyrrole disorder, low blood spermine and undermethylation. In all, it’s an unusual combination of bad biochemistry. A collaborative investigation with Pfeiffer resulted in nutrient therapies for each of the behavior types.

Pyrrole disorder is a stress condition commonly found in brain disorders. A urine test developed by niacin expert Abram Hoffer and Pfeiffer is the gold standard test for this genetic condition, which involves altered  biochemistry in your bone marrow and spleen.

People who have pyrrole disorder may produce five to 10 times more pyrroles than normal — a byproduct of natural reactions, like the formation of hemoglobin. While harmless in and of itself, pyrroles bind to and draw out anything that is an aldehyde, such as B-6. It also sharply depletes zinc.

As a result, people with pyrroles disorder have exceptionally low levels of B-6, and zinc which can have serious effects on brain function, affecting their memory and ability to read, for example. B-6 deficiency is quite common among children with attention deficit hyperactivity disorder (ADHD) as well.

The Earlier the Treatment the Better the Results

“Eventually, [Pfeiffer] and I jointly evaluated 500 patients, mostly violent adults and violent children. We got our best results with the kids, young people with the same kind of chemistry, who were mostly very violent,” Walsh says.

“I have to say we didn’t really succeed in finding a way to help the adult criminals. They would get better for six to eight months, and then I’d find out they were back in prison. That had a lot to do with the fact that they were abusing alcohol and illegal drugs … At about 1990, we decided to focus on children …

It’s been very successful. If we can get a child before their lives are ruined, before they pass puberty perhaps, our success rate [is] very high … The doctors report a striking improvement in behavior. Most of these kids, of course, [are] on drugs, everything from Ritalin to powerful antipsychotic  medications. Usually when we’re finished and [have] balanced their chemistry, they can wean off the medication. They usually are fine without it …”

Nutrients Involved in Synthesis or Functioning of Neurotransmitters Dictate Mental Function

Later on, Walsh expanded to also include children with autism and ADHD. Fond of numbers, Walsh began amassing enormous databases. At present, he has one of the world’s largest chemistry database for autismdepression and behavior disorders.

“When you look at these millions of chemical analyses of blood, urine and tissues, it’s obvious that there are very great differences,” he says. “I found that for mental disorders, about six or seven chemical imbalances dominate mental function. There are hundreds and hundreds of important nutrients in the body, but in the brain, there are about six or seven that [seem] to dominate everything. Eventually, I found out why …

[T]hese are the nutrient factors that are either involved in synthesis of a neurotransmitter or the functioning of a neurotransmitter. They include methylation — undermethylation or overmethylation. In our database, 70 percent of all humans in the United States have normal, typical methylation; 22 percent are undermethylated … 8 percent are overmethylated.

About 70 percent of all people who have a mental disorder have one of these methylation disorders. The symptoms are completely different, and the treatment they need is completely different. We also found that most people [who have mental disorders] are depleted or deficient in zinc. That’s the most common [deficiency] we see … Virtually everyone with a mental disorder seems to need zinc and improve on it.”

Copper Overload Linked to Autism, Schizophrenia and Postpartum Depression

Copper is another important trace metal, as it plays a distinct role in the synthesis of norepinephrine, a major neurotransmitter. Divalent copper (Cu2+) is a dramatic factor in the ratio of dopamine and norepinephrine. Read more here…

The Importance of Methylation and Folates in Mental Health

Walsh was among the first people to alert the world to the importance of methylation in mental health, especially autism. The No. 1 causes of undermethylation are single-nucleotide polymorphisms (SNPs) or mutations in the enzymes for the one-carbon cycle (the methylation cycle).base. The largest phenotype … is undermethylation. Read more here…

Changing the Face of Psychiatry

Walsh is convinced the use of psychiatric medication will eventually fade away as we learn more about normalizing brain function through nutritional interventions. “These powerful drugs … they do not normalize the brain. They cause an abnormal condition,” he warns. “They might correct depression or anxiety, but you wind up with something that’s not normal.”

The Walsh Research Institute is a public charity with no financial interests, and they are slowly but surely helping to change mainstream psychiatry. Walsh has given talks at the highest levels, including the Surgeon General’s office, the U.S. Senate and the National Institutes of Health (NIH). He’s also spoken at American Psychiatric Association (APA) annual meetings several times.

“The last time I went there, they finally listened to me … I was there about two and a half years ago. I gave an invited talk on depression. I basically explained to them they’re doing depression wrong. They actually listened to me. I showed them our huge chemistry database and explained that depression is a name given to at least five completely different disorders, each involving different symptoms and each involving different neurotransmitters that are malfunctioning.

Then I described each one of these biotypes and actually showed them that if they would simply do some inexpensive blood and urine testing, they could identify which people would be good candidates for selective serotonin reuptake inhibitors (SSRIs) or which ones would do better on benzodiazepine, but even more importantly, how they can correct it with nutrients.”

There were 17,000 psychiatrists at this meeting from all over the world, and Walsh was 1 of 4 speakers at a well-attended session. Afterward, there was tremendous demand for more information, which gives hope. Walsh also offers a training program for doctors. In the U.S., 45 psychiatrists went through the program last year. In all, 500 physicians and psychiatrists in 32 countries have taken his program so far.

Full Transcript at Dr Mercola’s Website

To learn more about Dr Walsh, visit www.WalshInstitute.org. There you can also purchase Walsh’s book, “Nutrient Power: Heal Your Biochemistry and Heal Your Brain.” Questions and information requests can be sent to Dana@WalshInstitute.org, or you can call (630) 506-5066.

“Our website has a resources section that recommends quality labs, compounding pharmacies and a list of doctors who we’ve trained, who are now able to do this kind of therapy,” Walsh says.

Alzheimer’s and MT Promoter Therapy

Alzheimer’s and MT Promoter developed by Dr William Walsh Phd.

NOTES FROM 10/18/16

Notes from Dr Walsh’s presentation at the October 2016 Physician Workshop and Training Conference.

Alzheimers was named after the Doctor bearing his name. Hallmarks of this condition include

  1. Apoptosis – spontaneous death of cells at rate of 5000 times normal.
  2. Severe oxidative stress – inflammation and tissue damage.
  3. Neurofibrillary tangles – twisted fibers inside brain cells. Derived from microtubules that are responsible for transporting nutrients to nerve cells.
  4. Metal problems – initially believed to be aluminum, then brain volume, then concentration of aluminum. Theory of metal toxicity is back in favor with issues of role of copper and zinc recognized as playing a more important role.

Dr Walsh has developed an amino acid blend, called MT Promoter which is intended to improve metallothionein protein production. One such protein, ceruloplasmin is important for binding or chelating ‘free metals’. Unbound copper and other metals are free radicals that cause tissue damage. From a neurotransmitter standpoint, free copper lowers dopamine, the reward and executive thought neurotransmitter, and raises levels of norepinephrine, an excitatory neurotransmitter.  To prevent this conversion and avoid other effects of oxidative stress, we like to increase these binding proteins. In addition to MT Promoter, binding proteins level improves with improved consumption and digestive uptake of protein.  Metallothionein proteins are found in border cells of the digestive track and brain. They are believed to be a first line of defense against free radical damage.

There are believed to be two types of Alzheimer’s conditions:

  1. Genetic – runs in some families – out of 5-6 siblings, 1-3 will get this, as they get progressively older
  2. ApoE – genetically expressed proteins – Believed now that 50% of people 85+ have some amount

 

Signs and symptoms of progressive worsening condition:

  1. Early warning signs – often as early as 55-60 years old
    1. Lose interest in schedules – move away from life
    2. MCI
    3. Why recent/old – as memories formed, as sensory nerves strike outer part of brain and lay down inputs, memories are processed, info transferred to hippocampus and base of brain parts, processed/organized, then back where it came from and laid down as memory
  2. Moderate symptoms
    1. Inability to form new memories
    2. Years 4-6
    3. Often require nursing home – though may not be bothered by this
  3. Later stage
    1. Awful
    2. Complete loss of speech and response
    3. Some may have some understanding of who’s there but unable to respond

Risk Factors for Alzheimer’s

  1. Only realized in mid-50s had something to do with age
    1. Prior didn’t have long enough lifespan
  2. Many documented cases of boxers
    1. Family of well-known boxers in England – all developed
    2. Also football players – more and more cases now
  3. Education – big surprise
    1. Someone in MI developed ability to measure amyloid plaque level in alive human being – proportional to disorder in autopsies
    2. People who never went past HS, vs. college – factor of 5 difference – Even stronger if didn’t finish 8th grade
  4. Keep mind as active as possible
    1. If retired and learn new language or learn something new
  5. Sedentary FAR more likely
  6. Vascular Alzheimer’s Disease – not vascular dementia
    1. Most begins very close to blood vessels
    2. People with hypertension AND hypotension are more prone
  7. Alcohol abuse – factor 2-3
  8. Toxic metals – seen in high levels
  9. Poor nutrition
    1. Lots to do with glial cells nourishing all neurons
    2. Need nutrition to stay healthy, or neurons deteriorate and die

 

Diagnostic tests for Alzheimer’s:

  1. MMSE – common
  2. Best test – CANTAB – from Yale
    1. Like video game test – spend 45” going through the test
    2. Measures many cognitive functions, not just memory
    3. He got that to test his people pre/post
  3. Odor discrimination – entorhinal cortex is first to go
    1. Scratch and sniff, differentiate smells in multiple choice
    2. Correctly tell 10+ – very low likelihood of Alzheimer’s Disease development
    3. If 2-4, chances within 5 years much higher
    4. He gave to a good friend, who flunked the test – dad had died of Alzheimer’s Disease
      1. Had been getting affairs in order, then found out had a bad cold that day!
      2. Totally normal on retest, repeated since
    5. Direct measure
      1. Not yet FDA approved – research only

Theories:

  1. Ach
  2. Amyloid – losing favor
    1. They have gunky material in brain when they die
    2. As it grows, when it touches neuron, it dies – they thought
    3. 12-13 years ago – discovered drug to eliminate plaque from rat brains, rushed to human testing
      1. At first, so exciting. Got rid of plaques with mild-mod Alzheimer’s Disease
      2. Bad news – didn’t change trajectory of disease – still deteriorate and die
    4. Tau
      1. Makes the tangles
      2. Still leading theory
    5. Inflammation
      1. Could be this alone?
      2. Curcumin theory – India incidence of Alzheimer’s Disease in old people – 90yo – very small
        1. Curcumin very able to reduce inflammation in brain
      3. Oxidative stress
        1. Present in almost every neurodegenerative condition
      4. Toxic metal causation
        1. Persuasive Alzheimer’s Disease research on copper
      5. Could also be glial and nutrition related

ApoE isoforms:

  1. Small protein, linear
  2. Cysteine is great antioxidant
  3. When replaced progressively by arginine, raises risk
  4. Most people with Apoe4 don’t get it – 40-45%
  5. 40% of Alzheimer’s Disease have neither

FDA approved:

  1. Can improve symptoms 6-12 months (actually 4-6 in practice)
  2. Does not stop progress
  3. Enables dying brain to function a bit better – just what’s left works better

Case for Metallothionein:

  1. As much as anything else in brain, protective of metals
  2. If don’t have above-average levels of these metals, highly unlikely to form plaques
  3. Fresh brains with and w/o Alzheimer’s Disease – those who died OF Alzheimer’s Disease had less than 1/3 of normal conc
  4. Very intriguing

MT Promoter for Alzheimers:

  1. He had already developed for autism
  2. Formulation of 22 nutrients that promote synth and fxn of MT
    1. They looked at over 900 studies to see which nutrients promote expression of Alzheimer’s Disease, and which promoted function of brain once expressed
    2. They found by taking it themselves that there ARE side effects if low in Zn
    3. Zn is a metal-regulating element actually on DNA – tends to promote expression of MT
    4. But, it gets expressed without Zn (naked molecule) which immediately grabs Zn, dropping blood level, and causing irritability
  3. Zn loading followed by MTP
    1. Do this till plasma zinc reaches 100 mcg/dL
  4. Aimed at overcoming brain oxidative stress and inflammation, and repair of the BBB
    1. Prevents bad stuff from coming in

MT Promoter for Alzheimer’s Disease:

  1. Unproven until RCTs confirm efficacy
  2. Very promising results
  3. Don’t give to anyone without good quality of life – don’t preserve them in state of misery, so NOT advanced
  4. Have to have caretaker

Scientific Article on Zinc Deficiency

Excellent Open Access Scientific Article on Zinc Deficiency

The article was reformatted so that Item 5 goes after 1, as deficiency is the question of concern here. As much as 1/3 of the worlds population is believed to be deficient in zinc. Toxicity is not a common problem as described below.

Int. J. Environ. Res. Public Health 2010, 7(4), 1342-1365; doi:10.3390/ijerph7041342

Review
The Essential Toxin: Impact of Zinc on Human Health
Laura M. Plum , Lothar Rink and Hajo Haase *
Institute of Immunology, Medical Faculty, RWTH Aachen University, Pauwelstrasse 30, 52074 Aachen, Germany; E-Mails: lplum@ukaachen.de (L.M.P.); lrink@ukaachen.de (L.R.)
*
Author to whom correspondence should be addressed; E-Mail: hhaase@ukaachen.de; Tel.: +49-241-808-0205; Fax: +49-241-808-2613.
Received: 27 January 2010; in revised form: 8 March 2010 / Accepted: 10 March 2010 /
Published: 26 March 2010

Abstract

Compared to several other metal ions with similar chemical properties, zinc is relatively harmless. Only exposure to high doses has toxic effects, making acute zinc intoxication a rare event. In addition to acute intoxication, long-term, high-dose zinc supplementation interferes with the uptake of copper. Hence, many of its toxic effects are in fact due to copper deficiency. While systemic homeostasis and efficient regulatory mechanisms on the cellular level generally prevent the uptake of cytotoxic doses of exogenous zinc, endogenous zinc plays a significant role in cytotoxic events in single cells. Here, zinc influences apoptosis by acting on several molecular regulators of programmed cell death, including caspases and proteins from the Bcl and Bax families. One organ where zinc is prominently involved in cell death is the brain, and cytotoxicity in consequence of ischemia or trauma involves the accumulation of free zinc. Rather than being a toxic metal ion, zinc is an essential trace element. Whereas intoxication by excessive exposure is rare, zinc deficiency is widespread and has a detrimental impact on growth, neuronal development, and immunity, and in severe cases its consequences are lethal. Zinc deficiency caused by malnutrition and foods with low bioavailability, aging, certain diseases, or deregulated homeostasis is a far more common risk to human health than intoxication.

Keywords:

toxicity; zinc; essential trace element

1. Introduction

In the periodic table of the elements, zinc can be found in group IIb, together with the two toxic metals cadmium and mercury. Nevertheless, zinc is considered to be relatively non-toxic to humans [1]. This is reflected by a comparison of the LD50 of the sulfate salts in rats. According to the Toxnet database of the U.S. National Library of Medicine, the oral LD50 for zinc is close to 3 g/kg body weight, more than 10-fold higher than cadmium and 50-fold higher than mercury [2]. An important factor seems to be zinc homeostasis, allowing the efficient handling of an excess of orally ingested zinc, because after intraperitoneal injection into mice, the LD50 for zinc was only approximately four-fold higher than for cadmium and mercury [3]. In contrast to the other two metals, for which no role in human physiology is known, zinc is an essential trace element not only for humans, but for all organisms. It is a component of more than 300 enzymes and an even greater number of other proteins, which emphasizes its indispensable role for human health. Optimal nucleic acid and protein metabolism, as well as cell growth, division, and function, require sufficient availability of zinc [4].

In this review, we will give a brief summary of zinc homeostasis, followed by a description of the effects of acute zinc intoxication and the consequences of long-term exposure to elevated amounts of zinc. Besides systemic intoxication, there exists evidence for a physiological involvement of endogenous zinc in toxicity on the cellular level, e.g., regulating apoptosis in many different cell types, and having a prominent role in neuronal death. In the end, we will also briefly discuss the detrimental effects of zinc deficiency, because, unless they are exposed to zinc in the workplace or by accident, healthy individuals are at far greater risk of suffering from the adverse effects associated with zinc deficiency than from those associated with intoxication.

5. Zinc Deficiency

As discussed above, systemic zinc toxicity is not a major health problem. On the other hand, due to its essentiality, a lack of this trace element leads to far more severe and widespread problems. Both, nutritional and inherited zinc deficiency generate similar symptoms [164], and clinical zinc deficiency causes a spectrum from mild and marginal effects up to symptoms of severe nature (Figure 2) [165].

Human zinc deficiency was first reported in 1961, when Iranian males were diagnosed with symptoms including growth retardation, hypogonadism, skin abnormalities, and mental lethargy, attributed to nutritional zinc deficiency [166]. Later studies with some Egyptian patients showed remarkably similar clinical features [167]. Additional studies in the ongoing years manifested zinc deficiency as a potentially widespread problem in developing as well as in industrialized nations [168].

Severe zinc deficiency can be either inherited or acquired. The most severe of the inherited forms is acrodermatitis enteropathica, a rare autosomal recessive metabolic disorder resulting from a mutation in the intestinal Zip4 transporter [169]. Symptoms of this condition include skin lesions, alopecia, diarrhea, neuropsychological disturbances, weight loss, reduced immune function, as well as hypogonadism in men, and can be lethal in the absence of treatment [170].

Acquired severe zinc deficiency has been observed in patients receiving total parental nutrition without supplementation of zinc, following excessive alcohol ingestion, severe malabsorption, and iatrogenic causes such as treatment with histidine or penicillamine [165]. The symptoms are mostly similar to those arising during acrodermatitis enteropathica.

Some reports indicate the existence of another group of inherited disorders of zinc metabolism. They lead to baseline zinc plasma levels above 300 μg/100 mL, more than three times the physiological level, while iron and copper levels stay normal [171173]. Even though this exceeds the amount normally found in serum after zinc intoxication, symptoms range from none to severe anemia, growth failure, and systemic inflammation, and resemble zinc deficiency rather than chronic or acute intoxication [172175]. The elevated zinc levels have been attributed to excessive binding to serum proteins, e.g., by albumin [171,173], or to overexpression of the zinc-binding S100 protein calprotectin [172,174]. Hence, the large amounts of zinc in the serum of these patients are sequestered by proteins, potentially even depleting biologically available zinc [175].

Clinical manifestations of moderate zinc deficiency are mainly found in patients with low dietary zinc intake, alcohol abuse, malabsorption, chronic renal disease, and chronic debilitation. Symptoms include growth retardation (in growing children and adolescents), hypogonadism in men, skin changes, poor appetite, mental lethargy, delayed wound healing, taste abnormalities, abnormal dark adaptation, and anergy [165].

Moderate zinc deficiency can also occur as a consequence of sickle cell disease [176]. Hyperzincuria and a high protein turnover due to increased hemolysis lead to moderate zinc deficiency in these patients, which causes clinical manifestations typical for zinc deficiency, such as growth retardation, hypogonadism in males, hyperammonemia, abnormal dark adaptation, and cell-mediated immune disorder [177] connected with thymic atrophy [178].

In mild cases of zinc deficiency, slight weight loss, oligospermia and hyperammonemia were observed [165]. One population in which mild zinc deficiency occurs with high prevalence, even in industrialized countries, are the elderly. Here, a significant proportion has reduced serum zinc levels, and zinc supplementation studies indicate that this deficiency contributes significantly to increased susceptibility to infectious diseases [44].

The overall frequency of zinc deficiency worldwide is expected to be higher than 20% [179]. In developing countries, it may affect more than 2 billion people [166,180182]. Furthermore, it has been estimated that only 42.5% of the elderly (≥71 years) in the Unites States have adequate zinc intake [183]. This widespread occurrence combined with the variety of clinical manifestations makes zinc deficiency a serious nutritional problem, which has a far greater impact on human health than the relatively infrequent intoxication with zinc.

6. Conclusions

Zinc is an essential trace element, and the human body has efficient mechanisms, both on systemic and cellular levels, to maintain homeostasis over a broad exposure range. Consequently, zinc has a rather low toxicity, and a severe impact on human health by intoxication with zinc is a relatively rare event.

Nevertheless, on the cellular level zinc impacts survival and may be a crucial regulator of apoptosis as well as neuronal death following brain injury. Although these effects seem to be unresponsive to nutritional supplementation with zinc, future research may allow influencing these processes via substances that alter zinc homeostasis, instead of directly giving zinc.

Whereas there are only anecdotal reports of severe zinc intoxication, zinc deficiency is a condition with broad occurrence and potentially profound impact. Here, the application of “negative zinc”, i.e., substances or conditions that deplete the body of zinc, constitute a major health risk. The impact ranges from mild zinc deficiency, which can aggravate infections by impairing the immune defense, up to severe cases, in which the symptoms are obvious and cause reduced life expectancy.

 

2. Zinc Homeostasis

The human body contains 2–3 g zinc, and nearly 90% is found in muscle and bone [5]. Other organs containing estimable concentrations of zinc include prostate, liver, the gastrointestinal tract, kidney, skin, lung, brain, heart, and pancreas [68]. Oral uptake of zinc leads to absorption throughout the small intestine and distribution subsequently occurs via the serum, where it predominately exists bound to several proteins such as albumin, α-microglobulin, and transferrin [9].

On the cellular level, 30–40% of zinc is localized in the nucleus, 50% in the cytosol and the remaining part is associated with membranes [4]. Cellular zinc underlies an efficient homeostatic control that avoids accumulation of zinc in excess (see also Figure 1a). The cellular homeostasis of zinc is mediated by two protein families; the zinc-importer (Zip; Zrt-, Irt-like proteins) family, containing 14 proteins that transport zinc into the cytosol, and the zinc transporter (ZnT) family, comprising 10 proteins transporting zinc out of the cytosol [10].

Ijerph 07 01342f1 1024
Figure 1. Cellular zinc homeostasis and its impact on cytotoxicity (A) Cellular zinc homeostasis is mediated by three main mechanisms. First, by transport through the plasma membrane by importers from the Zip-family, and export proteins from the ZnT-family. Second, by zinc-binding proteins such as metallothionein. Third, by transporter-mediated sequestration into intracellular organelles, including endoplasmic reticulum, Golgi, and lysosomes. Tight control of zinc homeostasis is required for maintenance of cellular viability, whereas deregulation leads to cell death. (B) A particular role in intracellular zinc homeostasis is played by the metallothionein/thionein-system. Free and loosely bound zinc ions are bound by the apo-protein thionein (Tred), to form metallothionein (MT). Elevated levels of free zinc ions can bind to zinc finger structures of the metal-regulatory transcription factor (MTF)-1, thus inducing the expression of thionein. Additionally, oxidation of thiols by reactive oxygen (ROS) or nitrogen (RNS) species triggers the formation of the oxidized protein thionin (Tox) with concomitant release of zinc.Click here to enlarge figure

The same transporter families also regulate the intracellular distribution of zinc into the endoplasmic reticulum, mitochondria, and Golgi. In addition, many mammalian cell types also contain membrane-bound vesicular structures, so-called zincosomes. These vesicles sequester high amounts of zinc and release it upon stimulation, e.g., with growth factors [11,12].

Finally, metallothioneins (MTs) play a significant role in zinc homeostasis by complexing up to 20% of intracellular zinc (Figure 1b) [13,14]. MTs are ubiquitous proteins, characterized by a low-molecular weight of 6–7 kDa, high cysteine content, and their ability to complex metal ions. One MT molecule can bind up to seven zinc ions. Through different affinities of the metal ion binding sites, it can act as a cellular zinc buffer over several orders of magnitude [15]. Dynamic regulation of cellular zinc by MT results from the synthesis of the apo-form thionein (T) in response to elevated intracellular zinc levels by triggering the metal response element-binding transcription factor (MTF)-1 [16]. In addition, oxidation of cysteine residues can alter the number of metal binding thiols, connecting redox and zinc metabolism. An in-depth discussion of this complex subject can be found in a recent review [17].

3. Exposure to Zinc

There are three major routes of entry for zinc into the humn body; by inhalation, through the skin, or by ingestion [18]. Each exposure type affects specific parts of the body (Figure 2) and allows the uptake of different amounts of zinc.

Figure 2. Comparison of the effects of zinc intoxication versusdeficiency. Intoxication by excessive exposure to, or intake of, zinc (left hand side), and deprivation of zinc by malnutrition or medical conditions (right hand side), have detrimental effects on different organ systems. Effects that could not be attributed to a certain organ system or affect several organs are classified as systemic symptoms.Click here to enlarge figure

3.1. Exposure by Inhalation

Inhalation of zinc-containing smoke generally originates from industrial processes like galvanization, primarily affecting manufacture workers. In addition, military smoke bombs contain zinc oxide or zinc chloride, making soldiers a group in which several cases of inhalation of zinc-containing fumes were described. For example, Homma and colleagues reported a case of two soldiers who developed adult respiratory distress syndrome (ARDS) upon exposure to a zinc chloride-containing smoke bomb [19]. The two men died 25 and 32 days after the accident, respectively. Another soldier was exposed to concentrated zinc chloride for several minutes during military training [20]. He also developed ARDS 48 h after exposure. After tracheal intubation and mechanical ventilation for eight days, he left the hospital, and four months after the incident he returned to work without any respiratory disorder [20]. There are a few additional reports of related incidents with smoke bombs having similar effects on the respiratory tract [21,22].

However, in none of the incidents there was unequivocal evidence that zinc was the main cause for the respiratory symptoms. Not only was no information about the concentrations available, but also the inhaled smoke contained several other ingredients besides zinc chloride. In addition, zinc chloride is generally caustic, so the effects could have risen from the specific properties of the compound, rather than being a direct effect of zinc intoxication.

The most widely known effect of inhaling zinc-containing smoke is the so-called metal fume fever (MFF), which is mainly caused by inhalation of zinc oxide. This acute syndrome is an industrial disease which mostly occurs by inhalation of fresh metal fumes with a particle size <1 μm in occupational situations such as zinc smelting or welding [23]. Symptoms of this reversible syndrome begin generally a few hours after acute exposure and include fever, muscle soreness, nausea, fatigue, and respiratory effects like chest pain, cough, and dyspnea [24]. The respiratory symptoms have been shown to be accompanied by an increase in bronchiolar leukocytes [23]. In general, MFF is not life-threatening and the respiratory effects disappear within one to four days [25].

Development of MFF is connected to the exposure level, but very little data is available concerning the zinc concentrations that trigger this syndrome [26]. Two volunteers developed MFF as a consequence of acute inhalation (10–12 minutes) of 600 mg zinc/m3 as zinc oxide [27]. Hammond and colleagues reported about workers who had shortness of breath and chest pain 2–12 hours following exposure to 320–580 mg zinc/m3 as zinc oxide [28]. Only small changes in forced expiratory flow were observed after exposure to 77 mg zinc/m3 (15–30 minutes) as zinc oxide [29]. Several reports of exposures to lower concentrations of zinc oxide (14 mg/m3 for eight hours, 8–12 mg zinc/m3 for up to three hours and 0.034 mg zinc/m3 for six to eight hours) did not result in symptoms of metal fume fever [28,30,31]. Today, the permissible exposure limit according to the Occupational Safety and Health Administration (OSHA) is 5 mg/m3 for zinc oxide (dusts and fumes) in workplace air during an 8-hour workday, 40-hour work week [32].

3.2. Dermal Exposure

Dermal absorption of zinc occurs, but the number of studies is limited and the mechanism is still not clearly defined. Agren and colleagues pointed out that the pH of the skin, the amount of zinc applied, and its chemical speciation influence the absorption of zinc [33,34].

In a study in which a 25% zinc oxide patch (2.9 mg/cm2) was placed on human skin for 48 hours, there was no evidence of dermal irritation [33]. In another study comparing the dermal effect of different zinc compounds in mice, rabbits, and guinea pigs, zinc chloride was clearly the strongest irritant, followed by zinc acetate, causing moderate, and zinc sulfate, causing low irritations. Consistent with the study by Agren, zinc oxide did not show any irritant effect on skin [35].

As mentioned above, zinc chloride is caustic, and the irritation does not necessarily indicate a toxic effect of zinc. In contrast to a potentially harmful effect of zinc on skin, it should be noted that zinc is a well-known supplement for topical treatment of wounds and several dermatological conditions [34,3638]. Based on the existing data, it can be concluded that dermal exposure to zinc does not constitute a noteworthy toxicological risk.

3.3. Oral Exposure

Due to its nature as an essential trace element, oral uptake of small amounts of zinc is essential for survival. The recommended dietary allowance (RDA) for zinc is 11 mg/day for men and 8 mg/day for women [39]. Lower zinc intake is recommended for infants (2–3 mg/day) and children (5–9 mg/day) because of their lower average body weights [39]. This is significantly below the LD50 value, which has been estimated to be 27 g zinc/day humans based on comparison with equivalent studies in rats and mice [18]. In general, uptake of such an amount is unlikely, because approximately 225–400 mg zinc have been determined to be an emetic dose [40]. However, there is one published report of a woman who died after oral intake of 28 g zinc sulfate. After ingestion, she started vomiting and developed tachycardia as well as hyperglycemia. She died five days later of hemorrhagic pancreatitis and renal failure [41].

Immediate symptoms after uptake of toxic amounts of zinc include abdominal pain, nausea, and vomiting. Additional effects include lethargy, anemia, and dizziness [42]. Particular effects of excessive oral zinc exposure are discussed in detail below.

Gastrointestinal Effects

The gastrointestinal tract is directly affected by ingested zinc, before it is distributed through the body. Therefore, multiple gastrointestinal symptoms after oral uptake of zinc have been reported. Brown et al.described several cases in which high zinc ingestion resulted from storage of food or drink in galvanized containers. Ingestion was caused by the moderately acidic nature of the food or drink, enabling the removal of sufficient zinc from the galvanized coating. The resulting symptoms included nausea and vomiting, epigastric pain, abdominal cramps, and diarrhea [40].

In a study by Samman and Roberts, symptoms such as abdominal cramps, vomiting and nausea occurred in 26 of 47 healthy volunteers following ingestion of zinc sulfate tablets, containing 150 mg elemental zinc, for six weeks [43]. However, similar doses have been used in several other zinc supplementation studies without comparable side effects [44].

In addition to zinc sulfate, other zinc compounds like zinc oxide and zinc gluconate also have a similar impact on the gastrointestinal system [4547]. A 39-year-old man showed nausea, vomiting, and abdominal pain six hours after ingesting 150 g of a 10% zinc oxide lotion, but without signs of systemic toxicity. Furthermore, he developed gastroduodenal corrosive injury. The symptoms persisted for three days and on the fifth day of admission, the corrosive injury showed regression without cicatrization [47].

Zinc-Induced Copper Deficiency

Taking up large doses of supplemental zinc over extended periods of time is frequently associated with copper deficiency [4850]. This correlation seems to be caused by the competitive absorption relationship of zinc and copper within enterocytes, mediated by MT. The expression of MT is upregulated by high dietary zinc content, and MT binds copper with a higher affinity than zinc. Consequently, available copper ions are bound by MT and the resulting complex is subsequently excreted [51,52]. Oestreicher and Cousins stated that the dietary intake of different doses of copper and zinc did not significantly alter the absorption of the other metal, as long as they were given at the same ratio, irrespective if 1 mg/kg copper and 5 mg/kg zinc, or up to 36 mg/kg copper together with 180 mg/kg zinc were given [53]. Nevertheless, copper absorption is depressed when zinc is given in high excess over copper [54].

Frequent symptoms of copper deficiency include hypocupremia, impaired iron mobilization, anemia, leukopenia, neutropenia, decreased superoxide dismutase (SOD) (particularly erythrocyte SOD (ESOD)), ceruloplasmin as well as cytochrome-c oxidase, but increased plasma cholesterol and LDL:HDL cholesterol and abnormal cardiac function [5557].

Furthermore, Irving and colleagues reported the case of a 19-year old woman who was supplemented with two doses of 50 mg zinc per day as part of a treatment of Hallervorden–Spatz syndrome, leading to a total daily intake of about 121.25 mg of zinc for more than 5 years, corresponding to approximately 15 times the RDA. Her daily intake of copper was 2 mg, which was approximately twice the RDA. As a result, she was markedly anemic and had severe neutropenia. Zinc-induced copper deficiency was confirmed by elevated serum zinc and low copper and ceruloplasmin serum levels. Four weeks after zinc therapy was stopped, all hematological and trace-metal parameters showed strong trends toward normalization and were normal after eight months [58].

Prasad and colleagues reported several cases of patients with sickle cell anemia who received 150 mg zinc/day and consequently showed low plasma copper, low ceruloplasmin, leukopenia, and anemia [59]. Another case report described a 31-year-old schizophrenic man who had been ingesting coins for 10 years [60]. He entered the hospital with symptoms including nausea, vomiting, and abdominal pain. Furthermore, profound anemia, neutropenia, and virtually absent serum copper and ceruloplasmin levels together with elevated zinc levels were diagnosed. Upon X-ray examination a large number of coins (totaling $22.50) were identified and surgically removed. Following the surgery, anemia and copper deficiency rapidly resolved. His copper deficiency was attributed to the ingestion of pennies, which since 1982 are composed of 98% zinc and 2% copper [60]. Several additional reports of zinc-induced copper deficiency leading to anemia and several other cytopenias were reviewed by Fiske and colleagues [55].

The mechanism by which copper deficiency induces anemia is based on the requirement of copper for several enzymes involved in iron transport and utilization and, therefore, in heme synthesis. For example, ceruloplasmin is a ferroxidase that binds copper and converts ferrous to ferric iron, allowing it to bind to transferrin and be transported. Cytochrome-c oxidase is also dependent on copper, and is required for the reduction of ferric iron to be incorporated into the heme molecule [6163]. In addition to interference with heme synthesis, copper deficiency causes approximately 85% reduction of ESOD in the red blood cell (RBC) membrane, decreasing RBC survival time [64].

Whereas a recent meta-analysis found no general effect of zinc supplementation on serum lipoproteins [65], it may occur as a consequence of disturbed copper homeostasis. Copper deficiency is related to alterations of serum cholesterol levels [57]. In healthy men, a daily intake of 160 mg zinc/day decreased HDL cholesterol significantly [66,67]. Also, young women who ingested 100 mg zinc/day showed a reduction in HDL cholesterol [68]. A study with 24 men who were fed omnivorous diets that were deficient in copper (0.89 mg) and high in zinc (21.4 mg), i.e., a Zn:Cu ratio of 23.5, showed low plasma copper, ESOD and HDL cholesterol, while LDL cholesterol was elevated [69]. This study was stopped after 11 weeks because four participants experienced cardiac abnormalities. Klevay and colleagues fed one man an omnivorous diet providing a Zn to copper ratio ≥ 16 for 105 days. Plasma copper and ceruloplasmin decreased, whereas total cholesterol and LDL cholesterol increased [70]. This experiment was ended when arrhythmia was detected. Taking into account several additional studies, Sandstead suggested that cardiac abnormalities were associated with Zn to copper ratios ≥16 [57].

Zinc Supplementation and Cancer

Whereas several other metals are well-known carcinogens, zinc is not generally considered to be a causative agent for cancer development. In contrast, displacement of zinc from zinc-binding structures, e.g., finger structures in DNA repair enzymes, may even be a major mechanism for carcinogenicity of other metals such as cadmium, cobalt, nickel, and arsenic [71].

One well investigated example in which an involvement of zinc in cancer development was suggested is prostate cancer. Notably, zinc levels in prostate adenocarcinoma are significantly lower than in the surrounding normal prostate tissues, suggesting an implication of zinc in the pathogenesis and progression of prostate malignancy [7274]. This is based on a down regulation of the zinc transporter Zip1, which is responsible for zinc uptake and accumulation in prostate cells [75,76].

Men with moderate to higher zinc intake may have a lower risk for prostate cancer, but the opposite may be true at extremely high doses and long-term supplementation [77]. A study by Leitzmann and colleagues examined the association between supplemental zinc intake and prostate cancer risk among 46,974 U.S. men. During 14 years, 2901 new cases of prostate cancer were observed, of which 434 were diagnosed as advanced cancer. Supplemental zinc intake at doses of up to 100 mg/day did not cause a higher prostate cancer risk, whereas long-term supplementation with higher doses increased the relative risk 2.9-fold [78]. This increased risk may not be due to direct carcinogenicity of zinc, because it is known that immunosuppression significantly increases the incidence of cancer, and, as discussed in the following paragraph, high doses of zinc can be immunosuppressive.

Immunological Effects

Sufficient availability of zinc is of particular importance to the immune system. Thereby, it plays a key role in multisided cellular and molecular mechanisms [79,80]. For instance, zinc influences the lymphocyte response to mitogens and cytokines, serves as a co-factor for the thymic hormone thymulin, and is involved in leukocyte signal transduction [8183]. An influence of zinc excess on T cell function was observed in several in vitro studies. In cell culture, very high zinc concentrations (above 100 μM) in a serum-free culture medium stimulate monocytes to secrete pro-inflammatory cytokines [84], but actually inhibit T cell functions. In general, T cells have a lower intracellular zinc concentration and are more susceptible to increasing zinc levels than monocytes [85,86]. Also, in vitro alloreactivity was inhibited in the mixed lymphocyte reaction (MLC) after treatment with more than 50 μM zinc [87]. A similar inhibition was observed when the MLC was done ex vivo with cells from individuals that had been supplemented with 80 mg zinc per day for one week, indicating that zinc supplementation has the potential to suppress the allogeneic immune response at relatively low doses [88].

An in vivo study supported the finding that zinc excess can affect lymphocyte function. 83 healthy volunteers ingested 330 mg zinc/ day in three doses for a month. The treatment had a small but significant influence on the lymphocyte response to the mitogens phytohemagglutinin (PHA) and Concanavalin A (Con A). Interestingly, it was observed that zinc had an immuno-regulatory influence, i.e., it decreased the lymphocyte response in high responders and had an enhancing effect on low responders [89].

4. The Role of Zinc in Cell Death

In addition to the systemic toxic effects of zinc, this metal is also involved in the regulation of live and death decisions on the cellular level. First, we will discuss its role in apoptosis. Second, we will focus on an organ where zinc toxicity has been investigated in great detail, the brain.

4.1. Impact of Zinc on Apoptosis

The exact role of zinc in the regulation of apoptosis is ambiguous. A variety of studies indicate that, depending on its concentration, zinc can either be pro- or anti-apoptotic, and both, zinc deprivation and excess, can induce apoptosis in the same cell line [9093].

The induction of apoptosis by high levels of intracellular zinc has been shown in different tissues and cell types [9395]. Reports indicate that accumulation of intracellular zinc, either as a consequence of exogenous administration or release from intracellular stores by reactive oxygen species or nitrosation, activates pro-apoptotic molecules like p38 and potassium channels, leading to cell death [93,9698]. Increased intracellular zinc levels may also induce cell death by inhibition of the energy metabolism [99,100].

Sensitive targets of zinc toxicity are the anti-apoptotic Bcl-2-like and pro-apoptotic Bax-like mitochondrial membrane proteins. In context of its apoptosis-inducing properties, zinc has been shown to increase the expression of Bax, leading to a decrease in the Bcl-2/Bax ratio [101]. As a consequence, dissipation of the mitochondrial membrane potential leads to the release of cytochrome-c from mitochondria into the cytosol [96,102105].

The anti-apoptotic properties of zinc likely comprise two main mechanisms. First, zinc limits the extent of damage induced during oxidative stress, thereby suppressing signaling pathways resulting in apoptosis. Second, zinc directly affects several proteins and pathways that regulate apoptosis.

Consistent with the first issue, zinc deficiency has been shown to induce oxidative stress [106108]. Mechanisms by which the redox-inert zinc protects cells against oxidative damage seem to include its property to protect sulfhydryl groups in proteins from oxidation [109]. Furthermore, by stabilizing lipids and proteins, zinc can preserve cellular membranes and macromolecules from oxidative damage. On the other hand, it has to be noted that elevated availability of zinc may also induce oxidative stress, and its impact on redox homeostasis may either be protective or promoting, depending on its availability [17].

With regard to the second mechanism, interaction of zinc with several apoptosis-regulating molecules has been reported. Zinc is a potent caspase-3 inhibitor [110] with an IC50 below 10 nM [111]. Furthermore, inhibition of caspases-6, -7, and -8 at low zinc concentrations was also shown, with caspase-6 being the most sensitive of the three [112].

Zinc deficiency can also induce apoptosis by disrupting growth factor signaling molecules such as ERK and Akt [113]. Other molecular targets for zinc are the anti-apoptotic Bcl-2-like and pro-apoptotic Bax-like mitochondrial membrane proteins. Zinc has been shown to increase the Bcl-2/Bax ratio, thereby increasing the resistance of the cells to apoptosis [114]. Consistent with this, in a study by Zalewski and colleagues apoptosis was induced in premonocytic cells by treatment with hydrogen peroxide. Supplementation with 1 mM zinc increased the ratio of Bcl-2 to Bax resulting in the inhibition of active caspase-3 and reduction of apoptosis [115]. Zinc-mediated apoptosis is abrogated by chelation with TPEN [116]. This is not undisputed, because it has also been shown in another study that zinc can increase the expression of Bax, leading to an decreased Bcl-2/Bax ratio and the release of cytochrome-c from mitochondria [101].

The influence of zinc on apoptosis is very complex and data are in part even contradictory. Amongst others, variables in this complex network are tissue and cell type, zinc concentration, expression of zinc transporters and zinc-binding proteins, other environmental circumstances like oxidative or nitrosative stress, and the involvement of multiple molecular targets with opposing functions.

4.2. Role of Zinc in Neuronal Death

A prominent and well investigated example for the control that zinc exerts on survival on the cellular level is the brain. This will now be discussed in more detail as an example of the mechanisms by which zinc can influence cellular survival.

Normally, homeostatic mechanisms should prevent zinc from accumulating in the brain to reach toxic concentrations as a result of excessive oral ingestion. However, there are reports of neurological symptoms following zinc intoxication, e.g., of a boy who showed lethargy and focal neurological deficits three days after he ingested 12 g of metallic zinc [117].

Many studies indicate that zinc acts as a neuromodulator [118121]. On the other hand, experimental evidence indicates that endogenous zinc might be a relatively potent, rapidly acting neurotoxin, and, to a lesser extent, also a gliotoxin [122126].

Zinc is stored in and released from vesicles in presynaptic terminals of a specific subset of neurons that also releases glutamate. Therefore, these neurons are defined as “gluzinergic” neurons [119, 127]. Zinc can be released from presynaptic terminals during synaptic transmission, enabling it to enter postsynaptic somata and dendrites of cells via zinc-permeable ion channels [105]. These channels include NMDA (N-methyl-D-aspartate)-gated channels [128], voltage-gated calcium channels [129,130] and the calcium-permeable AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)/kainate channel [131,132].

In addition to being sequestered in vesicles of presynaptic terminals in the gluzinergic neurons, zinc can also be bound to MT, especially MT-III, in perikarya as well as being taken up by mitochondria [133]. The MT-III isoform is found only in the brain and it is abundant in the gluzinergic neurons [134,135].

Exposure to 300–600 μM zinc for 15 minutes results in extensive neuronal death in cortical cell culture [136]. Considering that neurons store high amounts of free zinc in their terminals [137] that are released upon depolarization [138,139], zinc may play an active role in neuronal injury. Furthermore, membrane depolarization, which is associated with acute brain injury [140], greatly increases the potency of zinc to act as a neurotoxin [141]. Weiss et al. confirmed this by showing that depolarization with high concentrations (25 mM) of potassium media requires just a five minute-exposure to 100 μM zinc to kill all neurons in cortical cell culture [131].

Zinc has been described as a critical component of the excitotoxic cascade occurring after ischemia, seizures, and head trauma [141143]. The first study providing evidence that zinc accumulation may play a role in the selective death of dentate hilar neurons after global ischemia in rats was done by Tonder and colleagues [144]. In the meantime, zinc accumulation in dying or dead neurons has not only been shown in the hippocampal hilar region, but also in all brain regions damaged in global ischemia such as hippocampal CA1, neocortex, thalamus, and striatum [145]. Consistent with the hypothesis that zinc-accumulation may lead to neuronal cell death, this event was prevented by the intraventricular injection of the zinc-chelating agent CaEDTA [145].

Zinc release and accumulation of zinc ions was also observed in a rat model of traumatic brain injury, where Suh and colleagues showed that trauma is associated with loss of zinc from presynaptic boutons and appearance of zinc in injured neurons. Again, neuroprotection occurred by intraventricular administration of a zinc chelator [146].

For some time, vesicular zinc was thought to be the only releasable pool of zinc in the brain [127]. This led to the assumption that the zinc ions accumulating in injured neurons must be entirely of presynaptic origin [127], but when ZnT-3 knock-out mice were investigated, which lack histochemically reactive zinc in synaptic vesicles, they still showed zinc accumulation in degenerating neurons, pointing toward sources other than synaptic vesicular zinc [147]. Alternative dynamic zinc sources might be MT-III as well as mitochondrial stores in the postsynaptic neurons [148,149].

Although zinc is redox-inactive in biological systems and exists only as a bivalent cation, there is evidence that zinc toxicity in neurons is mediated mainly by oxidative stress [141]. Zinc-induced cell death is associated with increased levels of reactive oxygen species in neurons [150,151]. In addition, free-radical-generating enzymes like NADPH oxidase are induced and activated by exposure to zinc [152]. Finally, zinc-induced cell death has been shown to be attenuated by various antioxidant interventions [96,153].

Besides oxidative stress, nitrosative stress can also affect zinc-induced neuronal injury. Nitric monoxide plays a crucial role in zinc toxicity by releasing zinc ions from MT [154], and inhibition of nitric oxide synthase significantly reduces zinc release from brain slices during oxygen and glucose deprivation [155]. Consistent with this, Frederickson and colleagues observed that nitric oxide also rapidly releases zinc from presynaptic terminals [156].

In addition to the impact of zinc on apoptosis discussed above, zinc-induced apoptosis in neurons might be based on two additional mechanisms. First, zinc-exposed neurons show an induction of the neutrophin receptor p75NTR and p75NTR-associated death executor (NADE) [157], a combination that can trigger caspase activation and apoptosis [158]. Second, high intracellular zinc concentrations trigger dysfunction of neuronal mitochondria, resulting in the release of pro-apoptotic proteins such as cytochrome-c and apoptosis-inducing factor (AIF) [148].

Although the release of intracellular zinc triggers neuronal apoptosis [96,159,160], indicators of necrosis such as cell body swelling and destruction of intracellular organelles have also been observed [96,150], indicating that zinc-induced neuronal cell death might encompass both apoptotic and necrotic mechanisms [143]. Taken together, alterations of neuronal zinc homeostasis have a profound influence on cellular survival during acute insults, and zinc chelators are discussed as potential therapeutic agents for the treatment of stroke [161].

It seems likely that zinc is also involved in neurodegenerative diseases, e.g., zinc and a deregulated zinc homeostasis could be important to onset and progression of Alzheimer’s disease [162]. Here, the use of metal chelators such as clioquinol to restore normal neuronal zinc homeostasis has shown promising results in vivo [163].

References

  1. Fosmire, GJ. Zinc toxicity. Am. J. Clin. Nutr 1990, 51, 225–227. [Google Scholar]
  2. U. S. National Library of Medicine, Toxnet Database.
  3. Jones, MM; Schoenheit, JE; Weaver, AD. Pretreatment and heavy metal LD50 values. Toxicol. Appl. Pharmacol 1979, 49, 41–44. [Google Scholar]
  4. Vallee, BL; Falchuk, KH. The biochemical basis of zinc physiology. Physiol. Rev 1993, 73, 79–118. [Google Scholar]
  5. Wastney, ME; Aamodt, RL; Rumble, WF; Henkin, RI. Kinetic analysis of zinc metabolism and its regulation in normal humans. Am. J. Physiol 1986, 251, R398–R408. [Google Scholar]
  6. Bentley, PJ; Grubb, BR. Experimental dietary hyperzincemia tissue disposition of excess zinc in rabbits. Trace. Elem. Med 1991, 8, 202–207. [Google Scholar]
  7. He, LS; Yan, XS; Wu, DC. Age-dependent variation of zinc-65 metabolism in LACA mice. Int J. Radiat. Biol 1991, 60, 907–916. [Google Scholar]
  8. Llobet, JM; Domingo, JL; Colomina, MT; Mayayo, E; Corbella, J. Subchronic oral toxicity of zinc in rats. Bull. Environ. Contam. Toxicol 1988, 41, 36–43. [Google Scholar]
  9. Scott, BJ; Bradwell, AR. Identification of the serum binding proteins for iron, zinc, cadmium, nickel, and calcium. Clin. Chem 1983, 29, 629–633. [Google Scholar]
  10. Lichten, LA; Cousins, RJ. Mammalian zinc transporters: nutritional and physiologic regulation.Annu. Rev. Nutr 2009, 29, 153–176. [Google Scholar]
  11. Haase, H; Maret, W. Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling. Exp. Cell Res 2003, 291, 289–298. [Google Scholar]
  12. Taylor, KM; Vichova, P; Jordan, N; Hiscox, S; Hendley, R; Nicholson, RI. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells. Endocrinology 2008, 149, 4912–4920. [Google Scholar]
  13. Chimienti, F; Aouffen, M; Favier, A; Seve, M. Zinc homeostasis-regulating proteins: new drug targets for triggering cell fate. Curr. Drug Targets 2003, 4, 323–338. [Google Scholar]
  14. Tapiero, H; Tew, KD. Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed. Pharmacother 2003, 57, 399–411. [Google Scholar]
  15. Krezel, A; Maret, W. Dual nanomolar and picomolar Zn(II) binding properties of metallothionein.J. Am. Chem. Soc 2007, 129, 10911–10921. [Google Scholar]
  16. Laity, JH; Andrews, GK. Understanding the mechanisms of zinc-sensing by metal-response element binding transcription factor-1 (MTF-1). Arch. Biochem. Biophys 2007, 463, 201–210. [Google Scholar]
  17. Maret, W. Zinc coordination environments in proteins as redox sensors and signal transducers.Antioxid. Redox. Signal 2006, 8, 1419–1441. [Google Scholar]
  18. Toxicological Profile for Zinc; Agency for Toxic Substances and Disease Registry Division of Toxicology and Environmental Medicine: Atlanta, GA, USA, 2005.
  19. Homma, S; Jones, R; Qvist, J; Zapol, WM; Reid, L. Pulmonary vascular lesions in the adult respiratory distress syndrome caused by inhalation of zinc chloride smoke: a morphometric study.Hum. Pathol 1992, 23, 45–50. [Google Scholar]
  20. Freitag, A; Caduff, B. ARDS caused by military zinc fumes exposure. Schweiz Med. Wochenschr1996, 126, 1006–1010. [Google Scholar]
  21. Johnson, FA; Stonehill, RB. Chemical pneumonitis from inhalation of zinc chloride. Dis. Chest1961, 40, 619–624. [Google Scholar]
  22. Zerahn, B; Kofoed-Enevoldsen, A; Jensen, BV; Molvig, J; Ebbehoj, N; Johansen, JS; Kanstrup, IL. Pulmonary damage after modest exposure to zinc chloride smoke. Respir. Med 1999, 93, 885–890. [Google Scholar]
  23. Vogelmeier, C; Konig, G; Bencze, K; Fruhmann, G. Pulmonary involvement in zinc fume fever.Chest 1987, 92, 946–948. [Google Scholar]
  24. Rohrs, LC. Metal-fume fever from inhaling zinc oxide. AMA Arch. Ind. Health 1957, 16, 42–47. [Google Scholar]
  25. Brown, JJ. Zinc fume fever. Br. J. Radiol 1988, 61, 327–329. [Google Scholar]
  26. Martin, CJ; Le, XC; Guidotti, TL; Yalcin, S; Chum, E; Audette, RJ; Liang, C; Yuan, B; Zhang, X; Wu, J. Zinc exposure in Chinese foundry workers. Am. J. Ind. Med 1999, 35, 574–580. [Google Scholar]
  27. Sturgis, CC; Drinker, P; Thompson, RM. Metal fume fever: I. Clinical observations on the effect of the experimental inhalation of zinc oxide by two apparently normal persons. J. Ind. Hyg 1927,9, 88–97. [Google Scholar]
  28. Hammond, JW. Metal fume fever in crushed stone industry. J. Ind. Hyg 1944, 26, 117–119. [Google Scholar]
  29. Blanc, P; Wong, H; Bernstein, MS; Boushey, HA. An experimental human model of metal fume fever. Ann. Intern. Med 1991, 114, 930–936. [Google Scholar]
  30. Drinker, P; Thompson, RM; Finn, JL. Metal fume fever: IV. Threshold doses of zinc oxide, preventive measures, and the chronic effects of repeated exposures. J. Ind. Hyg 1927, 9, 331–345. [Google Scholar]
  31. Marquart, H; Smid, T; Heederik, D; Visschers, M. Lung function of welders of zinc-coated mild steel: cross-sectional analysis and changes over five consecutive work shifts. Am. J. Ind. Med1989, 16, 289–296. [Google Scholar]
  32. OSHA, Occupational Safety and Health Standards; Occupational Safety and Health Administration: Washington, DC, USA, 2003; Volume 29, CFR 1910.1000, pp. Table Z-1..
  33. Agren, MS. Percutaneous absorption of zinc from zinc oxide applied topically to intact skin in man. Dermatologica 1990, 180, 36–39. [Google Scholar]
  34. Agren, MS; Krusell, M; Franzen, L. Release and absorption of zinc from zinc oxide and zinc sulfate in open wounds. Acta Dermato.-Venereol 1991, 71, 330–333. [Google Scholar]
  35. Lansdown, AB. Interspecies variations in response to topical application of selected zinc compounds. Food. Chem. Toxicol 1991, 29, 57–64. [Google Scholar]
  36. Agren, MS; Franzen, L; Chvapil, M. Effects on wound healing of zinc oxide in a hydrocolloid dressing. J. Am. Acad. Dermatol 1993, 29, 221–227. [Google Scholar]
  37. Lansdown, AB. Influence of zinc oxide in the closure of open skin wounds. Int. J. Cosmet. Sci1993, 15, 83–85. [Google Scholar]
  38. Stromberg, HE; Agren, MS. Topical zinc oxide treatment improves arterial and venous leg ulcers.Br. J. Dermatol 1984, 111, 461–468. [Google Scholar]
  39. Trumbo, P; Yates, AA; Schlicker, S; Poos, M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet. Assoc 2001, 101, 294–301. [Google Scholar]
  40. Brown, MA; Thom, JV; Orth, GL; Cova, P; Juarez, J. Food poisoning involving zinc contamination. Arch. Environ. Health 1964, 8, 657–660. [Google Scholar]
  41. Fox, MRS. Zinc excess. In Zinc in Human Biology; Mills, CF, Ed.; Springer Verlag: New York, NY, USA, 1989; pp. 366–368. [Google Scholar]
  42. Porea, TJ; Belmont, JW; Mahoney, DH, Jr. Zinc-induced anemia and neutropenia in an adolescent.J. Pediatr 2000, 136, 688–690. [Google Scholar]
  43. Samman, S; Roberts, DC. The effect of zinc supplements on plasma zinc and copper levels and the reported symptoms in healthy volunteers. Med. J. Aust 1987, 146, 246–249. [Google Scholar]
  44. Haase, H; Overbeck, S; Rink, L. Zinc supplementation for the treatment or prevention of disease: current status and future perspectives. Exp. Gerontol 2008, 43, 394–408. [Google Scholar]
  45. Callender, GR; Gentzkow, CJ. Acute poisoning by the zinc and antimony content of limeade prepared in a galvanized iron can. Military Surgeon 1937, 80, 67–71. [Google Scholar]
  46. Lewis, MR; Kokan, L. Zinc gluconate: acute ingestion. J. Toxicol. Clin. Toxicol 1998, 36, 99–101. [Google Scholar]
  47. Liu, CH; Lee, CT; Tsai, FC; Hsu, SJ; Yang, PM. Gastroduodenal corrosive injury after oral zinc oxide. Ann. Emerg. Med 2006, 47, 296. [Google Scholar]
  48. Magee, AC; Matrone, G. Studies on growth, copper metabolism of rats fed high levels of zinc. J. Nutr 1960, 72, 233–242. [Google Scholar]
  49. Ogiso, T; Moriyama, K; Sasaki, S; Ishimura, Y; Minato, A. Inhibitory effect of high dietary zinc on copper absorption in rats. Chem. Pharm. Bull. (Tokyo) 1974, 22, 55–60. [Google Scholar]
  50. Van Campen, DR. Copper interference with the intestinal absorption of zinc-65 by rats. J. Nutr1969, 97, 104–108. [Google Scholar]
  51. Igic, PG; Lee, E; Harper, W; Roach, KW. Toxic effects associated with consumption of zinc.Mayo. Clin. Proc 2002, 77, 713–716. [Google Scholar]
  52. Ogiso, T; Ogawa, N; Miura, T. Inhibitory effect of high dietary zinc on copper absorption in rats. II. Binding of copper and zinc to cytosol proteins in the intestinal mucosa. Chem. Pharm. Bull1979, 27, 515–521. [Google Scholar]
  53. Oestreicher, P; Cousins, RJ. Copper and zinc absorption in the rat: mechanism of mutual antagonism. J. Nutr 1985, 115, 159–166. [Google Scholar]
  54. Fischer, PW; Giroux, A; L’Abbe, MR. The effect of dietary zinc on intestinal copper absorption.Am. J. Clin. Nutr 1981, 34, 1670–1675. [Google Scholar]
  55. Fiske, DN; McCoy, HE, III; Kitchens, CS. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am. J. Hematol 1994, 46, 147–150. [Google Scholar]
  56. Prohaska, JR. Biochemical changes in copper deficiency. J. Nutr. Biochem 1990, 1, 452–461. [Google Scholar]
  57. Sandstead, HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am. J. Clin. Nutr 1995, 61, 621S–624S. [Google Scholar]
  58. Irving, JA; Mattman, A; Lockitch, G; Farrell, K; Wadsworth, LD. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. CMAJ 2003, 169, 129–131. [Google Scholar]
  59. Prasad, AS; Brewer, GJ; Schoomaker, EB; Rabbani, P. Hypocupremia induced by zinc therapy in adults. JAMA 1978, 240, 2166–2168. [Google Scholar]
  60. Broun, ER; Greist, A; Tricot, G; Hoffman, R. Excessive zinc ingestion: a reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990, 265, 1441–1443. [Google Scholar]
  61. Frieden, E. The copper connection. Semin. Hematol 1983, 20, 114–117. [Google Scholar]
  62. Willis, MS; Monaghan, SA; Miller, ML; McKenna, RW; Perkins, WD; Levinson, BS; Bhushan, V; Kroft, SH. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am. J. Clin. Pathol 2005, 123, 125–131. [Google Scholar]
  63. Williams, DM. Copper deficiency in humans. Semin. Hematol 1983, 20, 118–128. [Google Scholar]
  64. Williams, DM; Lynch, RE; Lee, GR; Cartwright, GE. Superoxide dismutase activity in copper-deficient swine. Proc. Soc. Exp. Biol. Med 1975, 149, 534–536. [Google Scholar]
  65. Foster, M; Petocz, P; Samman, S. Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: A meta-analysis of randomised controlled trials. Atherosclerosis 2009. [Google Scholar]
  66. Black, MR; Medeiros, DM; Brunett, E; Welke, R. Zinc supplements and serum lipids in young adult white males. Am. J. Clin. Nutr 1988, 47, 970–975. [Google Scholar]
  67. Hooper, PL; Visconti, L; Garry, PJ; Johnson, GE. Zinc lowers high-density lipoprotein-cholesterol levels. JAMA 1980, 244, 1960–1961. [Google Scholar]
  68. Freeland-Graves, JH; Friedman, BJ; Han, WH; Shorey, RL; Young, R. Effect of zinc supplementation on plasma high-density lipoprotein cholesterol and zinc. Am. J. Clin. Nutr 1982,35, 988–992. [Google Scholar]
  69. Reiser, S; Powell, AS; Yang, C; Canary, J. Effect of copper intake on blood cholesterol and its lipoprotein distribution in men. Nutr. Rep. Int 1987, 36, 641–649. [Google Scholar]
  70. Klevay, LM; Inman, L; Johnson, LK; Lawler, M; Mahalko, JR; Milne, DB; Lukaski, HC; Bolonchuk, W; Sandstead, HH. Increased cholesterol in plasma in a young man during experimental copper depletion. Metabolism 1984, 33, 1112–1118. [Google Scholar]
  71. Beyersmann, D; Hartwig, A. Carcinogenic metal compounds: recent insight into molecular and cellular mechanisms. Arch. Toxicol 2008, 82, 493–512. [Google Scholar]
  72. Costello, LC; Franklin, RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998, 35, 285–296. [Google Scholar]
  73. Habib, FK. Zinc and the steroid endocrinology of the human prostate. J. Steroid. Biochem 1978, 9, 403–407. [Google Scholar]
  74. Zaichick, V; Sviridova, TV; Zaichick, SV. Zinc in the human prostate gland: normal, hyperplastic and cancerous. Int. Urol. Nephrol 1997, 29, 565–574. [Google Scholar]
  75. Costello, LC; Liu, Y; Zou, J; Franklin, RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J. Biol. Chem 1999, 274, 17499–17504. [Google Scholar]
  76. Franklin, RB; Feng, P; Milon, B; Desouki, MM; Singh, KK; Kajdacsy-Balla, A; Bagasra, O; Costello, LC. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.Mol. Cancer 2005, 4, 32. [Google Scholar]
  77. Jarrard, DF. Does zinc supplementation increase the risk of prostate cancer? Arch. Ophthalmol2005, 123, 102–103. [Google Scholar]
  78. Leitzmann, MF; Stampfer, MJ; Wu, K; Colditz, GA; Willett, WC; Giovannucci, EL. Zinc supplement use and risk of prostate cancer. J. Natl. Cancer Inst 2003, 95, 1004–1007. [Google Scholar]
  79. Honscheid, A; Rink, L; Haase, H. T-lymphocytes: a target for stimulatory and inhibitory effects of zinc ions. Endocr. Metab. Immune Disord. Drug Targets 2009, 9, 132–144. [Google Scholar]
  80. Rink, L; Gabriel, P. Zinc and the immune system. Proc. Nutr. Soc 2000, 59, 541–552. [Google Scholar]
  81. Delafuente, JC. Nutrients and immune responses. Rheum. Dis. Clin. North Am 1991, 17, 203–212. [Google Scholar]
  82. Fraker, PJ; DePasquale-Jardieu, P; Zwickl, CM; Luecke, RW. Regeneration of T-cell helper function in zinc-deficient adult mice. Proc. Nat. Acad. Sci. USA 1978, 75, 5660–5664. [Google Scholar]
  83. Haase, H; Rink, L. Functional significance of zinc-related signaling pathways in immune cells.Annu. Rev. Nutr 2009, 29, 133–152. [Google Scholar]
  84. Wellinghausen, N; Driessen, C; Rink, L. Stimulation of human peripheral blood mononuclear cells by zinc and related cations. Cytokine 1996, 8, 767–771. [Google Scholar]
  85. Bulgarini, D; Habetswallner, D; Boccoli, G; Montesoro, E; Camagna, A; Mastroberardino, G; Rosania, C; Testa, U; Peschle, C. Zinc modulates the mitogenic activation of human peripheral blood lymphocytes. Ann. Ist. Super. Sanita 1989, 25, 463–470. [Google Scholar]
  86. Wellinghausen, N; Martin, M; Rink, L. Zinc inhibits interleukin-1-dependent T cell stimulation.Eur. J. Immunol 1997, 27, 2529–2535. [Google Scholar]
  87. Campo, CA; Wellinghausen, N; Faber, C; Fischer, A; Rink, L. Zinc inhibits the mixed lymphocyte culture. Biol. Tr. Elem. Res 2001, 79, 15–22. [Google Scholar]
  88. Faber, C; Gabriel, P; Ibs, KH; Rink, L. Zinc in pharmacological doses suppresses allogeneic reaction without affecting the antigenic response. Bone Marrow Transplant 2004, 33, 1241–1246. [Google Scholar]
  89. Duchateau, J; Delepesse, G; Vrijens, R; Collet, H. Beneficial effects of oral zinc supplementation on the immune response of old people. Am. J. Med 1981, 70, 1001–1004. [Google Scholar]
  90. Cummings, JE; Kovacic, JP. The ubiquitous role of zinc in health and disease. J. Vet. Emerg. Crit. Care 2009, 19, 215–240. [Google Scholar]
  91. Formigari, A; Irato, P; Santon, A. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: biochemical and cytochemical aspects. Comp. Biochem. Physiol. Pt. C 2007,146, 443–459. [Google Scholar]
  92. Haase, H; Watjen, W; Beyersmann, D. Zinc induces apoptosis that can be suppressed by lanthanum in C6 rat glioma cells. Biol. Chem 2001, 382, 1227–1234. [Google Scholar]
  93. Truong-Tran, AQ; Carter, J; Ruffin, RE; Zalewski, PD. The role of zinc in caspase activation and apoptotic cell death. Biometals 2001, 14, 315–330. [Google Scholar]
  94. Fraker, PJ; Telford, WG. A reappraisal of the role of zinc in life and death decisions of cells. Proc. Soc. Exp. Biol. Med 1997, 215, 229–236. [Google Scholar]
  95. Watjen, W; Haase, H; Biagioli, M; Beyersmann, D. Induction of apoptosis in mammalian cells by cadmium and zinc. Environ. Health Perspect 2002, 110, 865–867. [Google Scholar]
  96. Kim, YH; Kim, EY; Gwag, BJ; Sohn, S; Koh, JY. Zinc-induced cortical neuronal death with features of apoptosis and necrosis: mediation by free radicals. Neuroscience 1999, 89, 175–182. [Google Scholar]
  97. McLaughlin, B; Pal, S; Tran, MP; Parsons, AA; Barone, FC; Erhardt, JA; Aizenman, E. p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. J. Neurosci 2001, 21, 3303–3311. [Google Scholar]
  98. Wiseman, DA; Wells, SM; Wilham, J; Hubbard, M; Welker, JE; Black, SM. Endothelial response to stress from exogenous Zn2+ resembles that of NO-mediated nitrosative stress, and is protected by MT-1 overexpression. Am. J. Physiol. Cell Physiol 2006, 291, C555–568. [Google Scholar]
  99. Brown, AM; Kristal, BS; Effron, MS; Shestopalov, AI; Ullucci, PA; Sheu, KF; Blass, JP; Cooper, AJ. Zn2+ inhibits alpha-ketoglutarate-stimulated mitochondrial respiration and the isolated alpha-ketoglutarate dehydrogenase complex. J. Biol. Chem 2000, 275, 13441–13447. [Google Scholar]
  100. Sheline, CT; Behrens, MM; Choi, DW. Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. J. Neurosci 2000, 20, 3139–3146. [Google Scholar]
  101. Feng, P; Li, T; Guan, Z; Franklin, RB; Costello, LC. The involvement of Bax in zinc-induced mitochondrial apoptogenesis in malignant prostate cells. Mol. Cancer 2008, 7, 25. [Google Scholar]
  102. Dineley, KE; Votyakova, TV; Reynolds, IJ. Zinc inhibition of cellular energy production: implications for mitochondria and neurodegeneration. J. Neurochem 2003, 85, 563–570. [Google Scholar]
  103. Feng, P; Li, TL; Guan, ZX; Franklin, RB; Costello, LC. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002, 52, 311–318. [Google Scholar]
  104. Mills, DA; Schmidt, B; Hiser, C; Westley, E; Ferguson-Miller, S. Membrane potential-controlled inhibition of cytochrome c oxidase by zinc. J. Biol. Chem 2002, 277, 14894–14901. [Google Scholar]
  105. Bitanihirwe, BK; Cunningham, MG. Zinc: the brain’s dark horse. Synapse 2009, 63, 1029–1049. [Google Scholar]
  106. Cui, L; Takagi, Y; Sando, K; Wasa, M; Okada, A. Nitric oxide synthase inhibitor attenuates inflammatory lesions in the skin of zinc-deficient rats. Nutrition 2000, 16, 34–41. [Google Scholar]
  107. Cui, L; Takagi, Y; Wasa, M; Sando, K; Khan, J; Okada, A. Nitric oxide synthase inhibitor attenuates intestinal damage induced by zinc deficiency in rats. J. Nutr 1999, 129, 792–798. [Google Scholar]
  108. Oteiza, PI; Clegg, MS; Zago, MP; Keen, CL. Zinc deficiency induces oxidative stress and AP-1 activation in 3T3 cells. Free Radical Biol. Med 2000, 28, 1091–1099. [Google Scholar]
  109. Williams, RJP. The biochemistry of zinc. Polyhedron 1987, 6, 61–69. [Google Scholar]
  110. Perry, DK; Smyth, MJ; Stennicke, HR; Salvesen, GS; Duriez, P; Poirier, GG; Hannun, YA. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J. Biol. Chem 1997, 272, 18530–18533. [Google Scholar]
  111. Maret, W; Jacob, C; Vallee, BL; Fischer, EH. Inhibitory sites in enzymes: zinc removal and reactivation by thionein. Proc. Nat. Acad. Sci. USA 1999, 96, 1936–1940. [Google Scholar]
  112. Stennicke, HR; Salvesen, GS. Biochemical characteristics of caspases-3, -6, -7, and -8. J. Biol. Chem 1997, 272, 25719–25723. [Google Scholar]
  113. Clegg, MS; Hanna, LA; Niles, BJ; Momma, TY; Keen, CL. Zinc deficiency-induced cell death.IUBMB Life 2005, 57, 661–669. [Google Scholar]
  114. Fukamachi, Y; Karasaki, Y; Sugiura, T; Itoh, H; Abe, T; Yamamura, K; Higashi, K. Zinc suppresses apoptosis of U937 cells induced by hydrogen peroxide through an increase of the Bcl-2/Bax ratio. Biochem. Biophys. Res. Commun 1998, 246, 364–369. [Google Scholar]
  115. Zalewski, PD; Forbes, IJ; Giannakis, C. Physiological role for zinc in prevention of apoptosis (gene-directed death). Biochem. Int 1991, 24, 1093–1101. [Google Scholar]
  116. Zalewski, PD; Forbes, IJ; Betts, WH. Correlation of apoptosis with change in intracellular labile Zn(II) using zinquin [(2-methyl-8-p-toluenesulphonamido-6-quinolyloxy)acetic acid], a new specific fluorescent probe for Zn(II). Biochem. J 1993, 296, 403–408. [Google Scholar]
  117. Murphy, JV. Intoxication following ingestion of elemental zinc. JAMA 1970, 212, 2119–2120. [Google Scholar]
  118. Colvin, RA; Fontaine, CP; Laskowski, M; Thomas, D. Zn2+ transporters and Zn2+ homeostasis in neurons. Eur. J. Pharmacol 2003, 479, 171–185. [Google Scholar]
  119. Frederickson, CJ; Bush, AI. Synaptically released zinc: physiological functions and pathological effects. Biometals 2001, 14, 353–366. [Google Scholar]
  120. Takeda, A. Movement of zinc and its functional significance in the brain. Brain. Res. Rev 2000,34, 137–148. [Google Scholar]
  121. Vogt, K; Mellor, J; Tong, G; Nicoll, R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 2000, 26, 187–196. [Google Scholar]
  122. Cuajungco, MP; Lees, GJ. Zinc and Alzheimer’s disease: is there a direct link? Brain. Res. Rev1997, 23, 219–236. [Google Scholar]
  123. Cuajungco, MP; Lees, GJ. Zinc metabolism in the brain: relevance to human neurodegenerative disorders. Neurobiol. Disease 1997, 4, 137–169. [Google Scholar]
  124. Frederickson, CJ; Suh, SW; Silva, D; Thompson, RB. Importance of zinc in the central nervous system: the zinc-containing neuron. J. Nutr 2000, 130, 1471S–1483S. [Google Scholar]
  125. Duncan, MW; Marini, AM; Watters, R; Kopin, IJ; Markey, SP. Zinc, a neurotoxin to cultured neurons, contaminates cycad flour prepared by traditional guamanian methods. J. Neurosci 1992,12, 1523–1537. [Google Scholar]
  126. Choi, DW; Yokoyama, M; Koh, J. Zinc neurotoxicity in cortical cell culture. Neuroscience 1988,24, 67–79. [Google Scholar]
  127. Frederickson, CJ. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol 1989, 31, 145–238. [Google Scholar]
  128. Koh, JY; Choi, DW. Zinc toxicity on cultured cortical neurons: involvement of N-methyl-D-aspartate receptors. Neuroscience 1994, 60, 1049–1057. [Google Scholar]
  129. Wang, YX; Quastel, DM. Multiple actions of zinc on transmitter release at mouse end-plates.Pflugers. Arch.-Eur. J. Physiol 1990, 415, 582–587. [Google Scholar]
  130. Colvin, RA; Davis, N; Nipper, RW; Carter, PA. Zinc transport in the brain: routes of zinc influx and efflux in neurons. J. Nutr 2000, 130, 1484S–1487S. [Google Scholar]
  131. Weiss, JH; Hartley, DM; Koh, JY; Choi, DW. AMPA receptor activation potentiates zinc neurotoxicity. Neuron 1993, 10, 43–49. [Google Scholar]
  132. Yin, HZ; Weiss, JH. Zn(2+) permeates Ca(2+) permeable AMPA/kainate channels and triggers selective neural injury. Neuroreport 1995, 6, 2553–2556. [Google Scholar]
  133. Sensi, SL; Ton-That, D; Weiss, JH. Mitochondrial sequestration and Ca(2+)-dependent release of cytosolic Zn(2+) loads in cortical neurons. Neurobiol. Disease 2002, 10, 100–108. [Google Scholar]
  134. Masters, BA; Quaife, CJ; Erickson, JC; Kelly, EJ; Froelick, GJ; Zambrowicz, BP; Brinster, RL; Palmiter, RD. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles.J. Neurosci 1994, 14, 5844–5857. [Google Scholar]
  135. Palmiter, RD; Findley, SD; Whitmore, TE; Durnam, DM. MT-III, a brain-specific member of the metallothionein gene family. Proc. Nat. Acad. Sci. USA 1992, 89, 6333–6337. [Google Scholar]
  136. Yokoyama, M; Koh, J; Choi, DW. Brief exposure to zinc is toxic to cortical neurons. Neurosci. Lett 1986, 71, 351–355. [Google Scholar]
  137. Frederickson, CJ; Klitenick, MA; Manton, WI; Kirkpatrick, JB. Cytoarchitectonic distribution of zinc in the hippocampus of man and the rat. Brain. Res 1983, 273, 335–339. [Google Scholar]
  138. Assaf, SY; Chung, SH. Release of endogenous Zn2+ from brain tissue during activity. Nature1984, 308, 734–736. [Google Scholar]
  139. Sloviter, RS. A selective loss of hippocampal mossy fiber Timm stain accompanies granule cell seizure activity induced by perforant path stimulation. Brain. Res 1985, 330, 150–153. [Google Scholar]
  140. Siesjo, BK. Basic mechanisms of traumatic brain damage. Ann. Emerg. Med 1993, 22, 959–969. [Google Scholar]
  141. Frederickson, CJ; Koh, JY; Bush, AI. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci 2005, 6, 449–462. [Google Scholar]
  142. Choi, DW; Koh, JY. Zinc and brain injury. Annu. Rev. Neurosci 1998, 21, 347–375. [Google Scholar]
  143. Weiss, JH; Sensi, SL; Koh, JY. Zn(2+): a novel ionic mediator of neural injury in brain disease.Trends. Pharmacol. Sci 2000, 21, 395–401. [Google Scholar]
  144. Tonder, N; Johansen, FF; Frederickson, CJ; Zimmer, J; Diemer, NH. Possible role of zinc in the selective degeneration of dentate hilar neurons after cerebral ischemia in the adult rat. Neurosci. Lett 1990, 109, 247–252. [Google Scholar]
  145. Koh, JY; Suh, SW; Gwag, BJ; He, YY; Hsu, CY; Choi, DW. The role of zinc in selective neuronal death after transient global cerebral ischemia. Science 1996, 272, 1013–1016. [Google Scholar]
  146. Suh, SW; Chen, JW; Motamedi, M; Bell, B; Listiak, K; Pons, NF; Danscher, G; Frederickson, CJ. Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury.Brain. Res 2000, 852, 268–273. [Google Scholar]
  147. Lee, JY; Cole, TB; Palmiter, RD; Koh, JY. Accumulation of zinc in degenerating hippocampal neurons of ZnT3-null mice after seizures: evidence against synaptic vesicle origin. J Neurosci2000, 20, RC79. [Google Scholar]
  148. Jiang, D; Sullivan, PG; Sensi, SL; Steward, O; Weiss, JH. Zn(2+) induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria. J. Biol. Chem2001, 276, 47524–47529. [Google Scholar]
  149. Sensi, SL; Ton-That, D; Sullivan, PG; Jonas, EA; Gee, KR; Kaczmarek, LK; Weiss, JH. Modulation of mitochondrial function by endogenous Zn2+ pools. Proc. Nat. Acad. Sci. USA2003, 100, 6157–6162. [Google Scholar]
  150. Kim, EY; Koh, JY; Kim, YH; Sohn, S; Joe, E; Gwag, BJ. Zn2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur. J. Neurosci 1999, 11, 327–334. [Google Scholar]
  151. Sensi, SL; Yin, HZ; Weiss, JH. Glutamate triggers preferential Zn2+ flux through Ca2+ permeable AMPA channels and consequent ROS production. Neuroreport 1999, 10, 1723–1727. [Google Scholar]
  152. Noh, KM; Koh, JY. Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci 2000, 20, RC111. [Google Scholar]
  153. Seo, SR; Chong, SA; Lee, SI; Sung, JY; Ahn, YS; Chung, KC; Seo, JT. Zn2+-induced ERK activation mediated by reactive oxygen species causes cell death in differentiated PC12 cells. J. Neurochem 2001, 78, 600–610. [Google Scholar]
  154. Aizenman, E; Stout, AK; Hartnett, KA; Dineley, KE; McLaughlin, B; Reynolds, IJ. Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release. J. Neurochem2000, 75, 1878–1888. [Google Scholar]
  155. Wei, G; Hough, CJ; Li, Y; Sarvey, JM. Characterization of extracellular accumulation of Zn2+during ischemia and reperfusion of hippocampus slices in rat. Neuroscience 2004, 125, 867–877. [Google Scholar]
  156. Frederickson, CJ; Cuajungco, MP; LaBuda, CJ; Suh, SW. Nitric oxide causes apparent release of zinc from presynaptic boutons. Neuroscience 2002, 115, 471–474. [Google Scholar]
  157. Park, JA; Lee, JY; Sato, TA; Koh, JY. Co-induction of p75NTR and p75NTR-associated death executor in neurons after zinc exposure in cortical culture or transient ischemia in the rat. J. Neurosci 2000, 20, 9096–9103. [Google Scholar]
  158. Mukai, J; Hachiya, T; Shoji-Hoshino, S; Kimura, MT; Nadano, D; Suvanto, P; Hanaoka, T; Li, Y; Irie, S; Greene, LA; Sato, TA. NADE, a p75NTR-associated cell death executor, is involved in signal transduction mediated by the common neurotrophin receptor p75NTR. J. Biol. Chem 2000,275, 17566–17570. [Google Scholar]
  159. Lobner, D; Canzoniero, LM; Manzerra, P; Gottron, F; Ying, H; Knudson, M; Tian, M; Dugan, LL; Kerchner, GA; Sheline, CT; Korsmeyer, SJ; Choi, DW. Zinc-induced neuronal death in cortical neurons. Cell. Mol. Biol 2000, 46, 797–806. [Google Scholar]
  160. Manev, H; Kharlamov, E; Uz, T; Mason, RP; Cagnoli, CM. Characterization of zinc-induced neuronal death in primary cultures of rat cerebellar granule cells. Exp. Neurol 1997, 146, 171–178. [Google Scholar]
  161. Barkalifa, R; Hershfinkel, M; Friedman, JE; Kozak, A; Sekler, I. The lipophilic zinc chelator DP-b99 prevents zinc induced neuronal death. Eur. J. Pharmacol 2009, 618, 15–21. [Google Scholar]
  162. Devirgiliis, C; Zalewski, PD; Perozzi, G; Murgia, C. Zinc fluxes and zinc transporter genes in chronic diseases. Mutat. Res 2007, 622, 84–93. [Google Scholar]
  163. Sensi, SL; Paoletti, P; Bush, AI; Sekler, I. Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci 2009, 10, 780–791. [Google Scholar]
  164. Ackland, ML; Michalczyk, A. Zinc deficiency and its inherited disorders: a review. Genes. Nutr2006, 1, 41–49. [Google Scholar]
  165. Prasad, AS. Clinical manifestations of zinc deficiency. Annu. Rev. Nutr 1985, 5, 341–363. [Google Scholar]
  166. Prasad, AS; Halsted, JA; Nadimi, M. Syndrome of iron deficiency anemia, hepatosplenomegaly, hypogonadism, dwarfism and geophagia. Am. J. Med 1961, 31, 532–546. [Google Scholar]
  167. Prasad, AS; Miale, AJ; Farid, Z; Sandstead, HH; Schulert, AR. Zinc metabolism in patients with the symptoms of iron deficiency, anaemia, hepatosplenomegaly, dwarfism and hypogonadism. J. Lab. Clin. Med 1963, 61, 537–549. [Google Scholar]
  168. Sandstead, HH. Zinc deficiency. A public health problem? Am. J. Dis. Child 1991, 145, 853–859. [Google Scholar]
  169. Wang, K; Zhou, B; Kuo, YM; Zemansky, J; Gitschier, J. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am. J. Hum. Genet 2002, 71, 66–73. [Google Scholar]
  170. Aggett, PJ. Acrodermatitis enteropathica. J. Inherit. Metab. Dis 1983, 6, 39–43. [Google Scholar]
  171. Failla, ML; van de Veerdonk, M; Morgan, WT; Smith, JC, Jr. Characterization of zinc-binding proteins of plasma in familial hyperzincemia. J. Lab. Clin. Med 1982, 100, 943–952. [Google Scholar]
  172. Fessatou, S; Fagerhol, MK; Roth, J; Stamoulakatou, A; Kitra, V; Hadarean, M; Paleologos, G; Chandrinou, H; Sampson, B; Papassotiriou, I. Severe anemia and neutropenia associated with hyperzincemia and hypercalprotectinemia. J. Pediatr. Hematol. Oncol 2005, 27, 477–480. [Google Scholar]
  173. Smith, JC; Zeller, JA; Brown, ED; Ong, SC. Elevated plasmz zinc: a heritable anomaly. Science1976, 193, 496–498. [Google Scholar]
  174. Saito, Y; Saito, K; Hirano, Y; Ikeya, K; Suzuki, H; Shishikura, K; Manno, S; Takakuwa, Y; Nakagawa, K; Iwasa, A; Fujikawa, S; Moriya, M; Mizoguchi, N; Golden, BE; Osawa, M. Hyperzincemia with systemic inflammation: a heritable disorder of calprotectin metabolism with rheumatic manifestations? J. Pediatr 2002, 140, 267–269. [Google Scholar]
  175. Sampson, B; Kovar, IZ; Rauscher, A; Fairweather-Tait, S; Beattie, J; McArdle, HJ; Ahmed, R; Green, C. A case of hyperzincemia with functional zinc depletion: a new disorder? Pediatr. Res1997, 42, 219–225. [Google Scholar]
  176. Prasad, AS. Zinc deficiency and effects of zinc supplementation on sickle cell anemia subjects.Prog. Clin. Biol. Res 1981, 55, 99–122. [Google Scholar]
  177. Prasad, AS. Zinc deficiency in patients with sickle cell disease. Am. J. Clin. Nutr 2002, 75, 181–182. [Google Scholar]
  178. Dardenne, M; Savino, W; Wade, S; Kaiserlian, D; Lemonnier, D; Bach, JF. In vivo and in vitrostudies of thymulin in marginally zinc-deficient mice. Eur. J. Immunol 1984, 14, 454–458. [Google Scholar]
  179. Wuehler, SE; Peerson, JM; Brown, KH. Use of national food balance data to estimate the adequacy of zinc in national food supplies: methodology and regional estimates. Public Health Nutr 2005, 8, 812–819. [Google Scholar]
  180. Cavdar, AO; Arcasoy, A; Cin, S; Babacan, E; Gozdasoglu, S. Geophagia in Turkey: iron and zinc deficiency, iron and zinc absorption studies and response to treatment with zinc in geophagia cases. Prog. Clin. Biol. Res 1983, 129, 71–97. [Google Scholar]
  181. Cavdar, OA. Zinc deficiency and geophagia. J. Pediatr 1982, 100, 1003–1004. [Google Scholar]
  182. Prasad, AS; Miale, A, Jr; Farid, Z; Sandstead, HH; Schulert, AR. Zinc metabolism in patients with the syndrome of iron deficiency anemia, hepatosplenomegaly, dwarfism, and hypognadism. J. Lab. Clin. Med 1963, 61, 537–549. [Google Scholar]
  183. Briefel, RR; Bialostosky, K; Kennedy-Stephenson, J; McDowell, MA; Ervin, RB; Wright, JD. Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988–1994. J. Nutr 2000, 130, 1367S–1373S. [Google Scholar]

Assessing Cause and Treating Autistic Kids and Autism Spectrum Adults

Focus on detoxification, immune status and brain biochemistry
A leaky gut syndrome is an inflammatory condition in the digestive track often brought on by allergies to foods such as dairy and wheat. It is also prominent with kids and adults that have elevated yeast or candida. This is either diet related, immune related or has to do with an imbalance of probiotics. The consequence is that toxins, brain toxins leak out of the digestive tract and affect the brain cells. The natural antioxidants that prevent this consequence of leaky gut includes glutathione. To correct leaky gut we test the conditions of the stool and improve the status of digestive enzymes, probiotics, HCL and status of candida.

Casein, Gluten and Autism
According to researchers from Penn State a gluten-free, casein-free diet may lead to improvements in behavior and physiological symptoms in children diagnosed with ASD.

“Research has shown that children with ASD commonly have GI [gastrointestinal] symptoms,” said Christine Pennesi, medical student at Penn State College of Medicine. “Notably, a greater proportion of our study population reported GI and allergy symptoms than what is seen in the general pediatric population. Some experts have suggested that gluten- and casein-derived peptides cause an immune response in children with ASD, and others have proposed that the peptides could trigger GI symptoms and behavioral problems.”

“Gluten and casein seem to be the most immunoreactive,” Klein said. “A child’s skin and blood tests for gluten and casein allergies can be negative, but the child still can have a localized immune response in the gut that can lead to behavioral and psychological symptoms. When you add that in with autism you can get an exacerbation of effects.”

“If parents are going to try a gluten-free, casein-free diet with their children, they really need to stick to it in order to receive the possible benefits,” she said.


Metallothionein and Autism – MT Therapy
In October of 2001, a team of clinicians and researchers led by William Walsh, Ph.D. then at the Pheiffer Treatment Center, affiliated with the Health Research Institute now of Warrenville, IL, made available a scientific study entitled “Metallothionein and Autism”. Metallothionein is a protein that is critical to the process of detoxification of harmful substances, particularly heavy metals and toxic chemicals.
The paper describes a study of 503 patients on the autism spectrum vs. aged-matched non-autistic patients. The conclusion of this study was that “most autistic patients exhibit evidence of metallothionein (MT) dysfunction and this dysfunction may be a universal characteristic of autism-spectrum disorders”.
Correcting an impaired detoxification system in ASD autistic children.
William Walsh PhD believes that “MT dysfunction and autism may result from the intersection of two factors: (a) a genetic defect involving marginal or defective MT functioning, followed by (b) an environmental insult during early development which disables MT.”

Dr David Epstein D.O., Medical Director at Second Opinion Physician studied under William Walsh and received certification in applying the Walsh Protocol to autistic kids and autistic adults. The focus of therapy is based on a standard set of labs that are ordered for children to identify and correct biochemical factors that disable MT proteins. These include (a) severe zinc depletion, (b) abnormalities in the glutathione redox system, (c) cysteine deficiency, and (d) malfunction of metal regulating elements (MRE’s).”

Glutathione is a key amino acid in the role of detoxifying the cells of the those on the autistic spectrum including those with aspergers symptoms. It is a product of metabolism in the methionine cycle. With autistics there are very low to no levels of glutathione produced. Low levels lead to other processes that include the dysfunction of methylation and sulfation.

The treatment protocol at Second Opinion Physician for autistic kids and adults on the spectrum recognizes the importance of the Walsh panel for brain function performance assessment. Correction is based on the restoration of the detoxification pathways for removing metals, strengthening the immune system, repair of the gut and brain cells, regulation of zinc and copper levels in the blood and prevention of yeast overgrowth.
The tests include identifying methylation status. Impaired methylation impairs suflation. Sulfation improves the digestive tract, brain function and connective tissues of the body. It also facilitates the production of glutathione and prevents cellular breakdown by removing toxic metals from within the cell.

Second Opinion Physician tests for ASD autistic disorder include the following:
1. Histamine for determining methylation status
2. Zinc and copper levels to identify degree of oxidative stress due to reactive metals causing free radical toxicity.
3. Ceruloplasmin – a copper metallothionein that neutralizes the oxidative effects of copper and other metals.
4. Urinary pyrroles – inflammatory element that depletes the body of B6 and zinc, both critical to brain function
5. Testing for Casein and Gluten allergies
6. CDSA comprehensive digestive stool analysis for evidence of yeast overgrowth, probiotic status and digestive capacity.
7. Vitamin D levels to determine need to supplement for immune improvement

Based on results from tests and historical assessment, Second Opinion Physician natural health care plan will likely include one or more supplement strategies:
1. Correcting methylation imbalance either through slowing down or increasing methylation
2. Improving MT status with a blend of amino acids with high sulfur. The formula was made available to Walsh-Certified physicians.
3. Restoring gut health with sulfur through sulfur containing amino acids and MSM.
4. Diet modification with casein free casein free diet to eliminate allergens
5. Replace probiotics and control candida yeast
6. Supplement with methionine and B12 for undermethylated ASD children
7. Increase zinc and lower copper with supplementation of proper dose and form of trace minerals.
8. Managing pyrrole disorder with B6 and zinc when tests warrant.
9. Vitamin D supplementation

Copper and Emotions

The effect of elevated total or free copper on neurotransmitters is significant. As a cofactor in the conversion of dopamine to norepinephrine, the effect of copper and emotions is profound. Dopamine is a mood enhancing, feel good neurotransmitter. And there is an important need for dopamine to convert to norepinephrine. But there needs to be a balance. When there’s too little dopamine and too much norepinephrine, which occurs in the presence of elevated copper, the effect of copper and emotions is important to address. 

Elevated copper is an indication that the body is having a difficult time managing free radicals and heavy metals. This often occurs when there is insufficient amino acid uptake to produce important metal binding metalothionine’s, such as ceruloplasmin, which binds free copper and neutralizes it. An excess of other heavy metals, which can be characterized as oxidative stress, also leads to a general inability to neutralize and mobilize metals such as copper. Lead, mercury, cadmium and aluminum are examples of the most reactive of free radicals. We are exposed to oxidative heavy metals from the air, water and soil. We are exposed through industrial pollutants, silver fillings, smoke, skin products, etc. Metals are a major reason for taking anti-oxidant free radical scavengers.

At Second Opinion Physician we will check your hair, plasma, serum and whole blood to get a good picture of your oxidative stres and the potential impact of copper and emotions. If you’ve already had these tests, let us know your results and we will prepare a supplements and lifestyle plan to get levels back on track.

Copper and Emotions

…the main thing that happens with metal retention is copper toxicity because everybody is getting copper constantly. Almost everything you eat has some copper in it. A lot of really popular foods like coffee, chocolate, avocado, soy, shellfish like shrimp and lobster, and certain beans and nuts like pecans are pretty high in copper.

This isn’t a problem with good liver, gall bladder and especially adrenal function. If adrenal function is strong, we just mobilize that copper and excrete it through the bile. Unfortunately, the way we live these days, that is not what is happening. Most people are not able to get rid of the excess copper. How many people have impaired liver function, congested gallbladder or adrenal fatigue? Probably the majority these days.

If adrenal function becomes impaired, the copper builds up in the liver, brain, joints and lungs. When this happens, you see very specific problems, including mental problems, liver problems and detoxification problems. Phase II liver impairment is often made worse by copper toxicity , if not actually caused by it.

You also see a lot of copper toxicity with asthma and breathing problems, including emphysema. Copper also tends to build up in the joints, leading to arthritis. Chronic skin problems are also an indication of copper toxicity .

Vegetarian diets are very high in copper because the vegetable foods are a great source of this mineral. Since vegetarians don’t eat meat, and possibly not even eggs, they are not getting enough zinc, which is the natural antagonist to copper. Zinc naturally balances copper and keeps it from building up in the tissues. If you are not eating much in the way of meat and eggs, you will develop copper problems.

Excess copper interferes with energy production at the cellular level. It impairs various energy pathways in the cell so it contributes to the very fatigue that tends to make you retain copper, leading to a vicious circle. Once this pattern gets going, it is totally self-reinforcing and very difficult to break, even by adding zinc-rich foods back into the diet.

Copper is an excitotoxin, and is stimulating to the brain. This is why you will see copper toxicity in manic states like paranoid and bi-polar disorder. The so-called copper head tends to be very emotional, very intense, often very creative. Such individuals are prone to crash and burn because their overactive mind is being supported by a very fatigued body.

Copper toxicity is a major factor in irritable bowel syndrome because copper is excreted through the bile and certain things will cause you to suddenly dump copper. If you have been building up copper, anything that causes an increase in your metabolic rate will cause a copper dump and it comes out through the bile. If you are copper toxic and suddenly under a lot of stress, this may bring on an irritable bowel episode because suddenly excess copper is moving through your bowels and irritating them.

The tendency of copper to build up in the body is similar to iron, which is another essential nutrient that is also a heavy metal. They’re both highly electrical, very conductive metals that produce a lot of free radical activity and have to be bound by special proteins, such as ceruloplasmin and metallothioine. The production of these proteins is controlled by the adrenal glands, and they are produced in the liver. If the adrenals are not functioning properly and the liver is impaired, possibly from copper buildup, you will not produce these binding proteins, so copper remains in free form. That makes it a toxic and reactive free-radical generator capable of causing a lot of damage.

The increase in copper is stimulating, it gets you going, which is just what you need in the short term. But chronic unremitting stress never gives you time to recover, you never get to address your biochemical imbalance, you never have that down time to excrete the excess copper now.

When your adrenal glands are in great shape, you can excrete excess copper whenever you need to. But when your adrenal glands are just hanging on by their fingernails, just barely able to mount a stress response, you have an excess of stimulating copper. It becomes very hard to go to sleep and the mind races. You think, think, think, worry, worry, worry, and all of that makes it worse. You are always worn out. In fact, people with chronic fatigue often wake up tired because they don’t really ever rest.